Atara Biotherap (ATRA) Stock Price, Quote & News

Company Profile

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Ket...

Industry: Biotechnology

Sector: Healthcare

Phone: 805 623 4211

Website: www.atarabio.com

Address:

1280 Rancho Conejo Blvd, Thousand Oaks, United States

Smurfologist Jul. 30 at 4:56 PM

$ATRA is showin' out for them doubters out there; YOU BETTA RECOGNIZE!!! 🙏🏾🐃💪🏾💣💥🚀

0 · Reply

VENIVICI Jul. 25 at 6:49 PM

Holding $ATRA tight into quarterly earnings. 🍿🍿🍿

3 · Reply

Smurfologist Jul. 25 at 2:27 PM

$ATRA Stocks rise; stocks fall.....THAT'S WHUT STOCKS DO. When stocks do whut they do, what matters is whut YOU do!! Gonna stack my chips so that when this stock bounce up, my pockets will git phat!!! There will always be haters out there. You have to do YOU!! Good luck to those that will stick around for the prize!! 🙏🏾🐃💪🏾💣💥🚀

0 · Reply

Newe0815 Jul. 24 at 9:44 PM

$ATRA The run will now probably be over, the hope was probably on a Class 1 classification. Now there will be nothing to report until January.

1 · Reply

takingstock73 Jul. 24 at 5:05 PM

$ATRA class 1 would have been better , but I think it still academic from here , just won't have 100% til Jan

0 · Reply

Lazyhitman817 Jul. 24 at 4:32 PM

$ATRA what was the sell off after pre market… was the approval of resubmission good ?

0 · Reply

prismmarketview Jul. 24 at 1:26 PM

Nasdaq: $ATRA @Atarabio’ tab-cel has received FDA Priority Review for EBV+ PTLD, a rare post-transplant cancer. A decision is expected by Jan 15, 2025—potentially making it the first approved therapy for this life-threatening disease. https://prismmarketview.com/atara-biotherapeutics-tab-cel-receives-fda-priority-review-for-ebv-post-transplant-lymphoproliferative-disease/

0 · Reply

BigSqueezeComing Jul. 24 at 1:09 PM

$ATRA PT 14

0 · Reply

BigSqueezeComing Jul. 24 at 1:09 PM

$ATRA https://www.businesswire.com/news/home/20250724273588/en/Atara-Biotherapeutics-Announces-U.S.-FDA-Acceptance-and-Priority-Review-of-the-Biologics-License-Application-for-Tabelecleucel-Tab-cel-for-the-Treatment-of-Epstein-Barr-Virus-Positive-Post-Transplant-Lymphoproliferative-Disease

0 · Reply

BigSqueezeComing Jul. 24 at 1:03 PM

$ATRA Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) By PR Newswire | July 24, 2025, 8:57 AM

0 · Reply

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Jul 24, 2025, 8:00 AM EDT - 6 days ago

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Jul 15, 2025, 8:00 AM EDT - 15 days ago

Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.

Jul 14, 2025, 8:00 AM EDT - 16 days ago

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

May 16, 2025, 8:50 PM EDT - 2 months ago

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

May 15, 2025, 8:35 AM EDT - 2 months ago

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

May 15, 2025, 8:30 AM EDT - 2 months ago

Atara Biotherapeutics Announces Pricing of $16 Million Offering

May 5, 2025, 5:06 PM EDT - 3 months ago

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

Mar 7, 2025, 4:01 PM EST - 5 months ago

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Mar 1, 2025, 11:00 AM EST - 5 months ago

The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Feb 15, 2025, 11:00 AM EST - 5 months ago

The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Feb 14, 2025, 8:11 AM EST - 5 months ago

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

Feb 11, 2025, 7:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation

Feb 10, 2025, 7:00 AM EST - 6 months ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Feb 9, 2025, 7:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation

Feb 7, 2025, 4:01 PM EST - 6 months ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 7:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect

Feb 6, 2025, 7:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect

Feb 5, 2025, 7:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation

Feb 4, 2025, 7:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation

Feb 3, 2025, 11:00 AM EST - 6 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud

Feb 3, 2025, 7:00 AM EST - 6 months ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 31, 2025, 7:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation

Jan 30, 2025, 7:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation

Jan 29, 2025, 7:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out

Jan 28, 2025, 11:00 AM EST - 6 months ago

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Atara Biotherapeutics, Inc. For Securities Fraud

Jan 28, 2025, 7:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out

Jan 28, 2025, 3:23 AM EST - 6 months ago

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Jan 27, 2025, 8:30 PM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect

Jan 21, 2025, 1:11 PM EST - 6 months ago

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

Jan 21, 2025, 7:30 AM EST - 6 months ago

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

Jan 21, 2025, 12:21 AM EST - 6 months ago

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

Jan 16, 2025, 8:41 AM EST - 6 months ago

US FDA declines to approve Atara Biotherapeutics' cancer therapy

Jan 16, 2025, 8:30 AM EST - 6 months ago

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Nov 27, 2024, 4:01 PM EST - 8 months ago

Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference

Nov 13, 2024, 4:01 PM EST - 9 months ago

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference

Nov 12, 2024, 4:01 PM EST - 9 months ago

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress

Smurfologist Jul. 30 at 4:56 PM

$ATRA is showin' out for them doubters out there; YOU BETTA RECOGNIZE!!! 🙏🏾🐃💪🏾💣💥🚀

0 · Reply

VENIVICI Jul. 25 at 6:49 PM

Holding $ATRA tight into quarterly earnings. 🍿🍿🍿

3 · Reply

Smurfologist Jul. 25 at 2:27 PM

0 · Reply

Newe0815 Jul. 24 at 9:44 PM

$ATRA The run will now probably be over, the hope was probably on a Class 1 classification. Now there will be nothing to report until January.

1 · Reply

takingstock73 Jul. 24 at 5:05 PM

$ATRA class 1 would have been better , but I think it still academic from here , just won't have 100% til Jan

0 · Reply

Lazyhitman817 Jul. 24 at 4:32 PM

$ATRA what was the sell off after pre market… was the approval of resubmission good ?

0 · Reply

prismmarketview Jul. 24 at 1:26 PM

0 · Reply

BigSqueezeComing Jul. 24 at 1:09 PM

$ATRA PT 14

0 · Reply

BigSqueezeComing Jul. 24 at 1:09 PM

0 · Reply

BigSqueezeComing Jul. 24 at 1:03 PM

0 · Reply

ballyhooo Jul. 24 at 12:38 PM

$ATRA The BLA has been granted Priority Review with a Class 2 Resubmission Prescription Drug User Fee Act (PDUFA) target action date of January 10, 2026.

0 · Reply

ballyhooo Jul. 24 at 12:01 PM

$ATRA Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

0 · Reply

Smurfologist Jul. 23 at 5:55 PM

$ATRA Profit-taking?!? 🙏🏾🐃💪🏾💣💥🚀

0 · Reply

Smurfologist Jul. 23 at 2:20 PM

$ATRA $13.50?!? I think she got it in her......LET'S GO, GURL!!!🙏🏾🐃💪🏾💣💥🚀

0 · Reply

moncor Jul. 22 at 11:47 PM

$ABVX watch out guys...next will be $ATRA!!!!

1 · Reply

moncor Jul. 22 at 11:45 PM

$ABVX for those of you who missed this monster move like me, check out $ATRA. This will be running fast to the fifty's or hundreds soon...Congrats to all those who have $ABVX. Soon it will be $ATRA!!!!

0 · Reply

BullRun4 Jul. 22 at 7:32 PM

$ATRA very bullish

0 · Reply

Smurfologist Jul. 22 at 5:47 PM

$ATRA JUST WoW!!!🙏🏾🐃💪🏾💣💥🚀

0 · Reply

Smurfologist Jul. 22 at 2:00 PM

$ATRA is showing out rat now.....Are we good for $13.00 today?!? ALL ABOARD!!! 🙏🏾🐃💪🏾💣💥🚀

0 · Reply

takingstock73 Jul. 22 at 1:59 PM

$ATRA low volume run , any theories ?

0 · Reply

Lazyhitman817 Jul. 22 at 1:48 PM

$ATRA has this on my watchlist for a week and got in yesterday based off my indicators as it’s apparent it will run for little, but anyone know the reason for this little breakout or what? Or is it solely technical

1 · Reply

hassle Jul. 22 at 8:06 AM

0 · Reply

Market Cap	70.40M
Revenue (ttm)	128.94M
Net Income (ttm)	-85.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-66.23%
Debt to Equity Ratio	0.00

Volume	90,400
Avg Vol	63,094
Day's Range	N/A - N/A
Shares Out	5.96M
Stochastic %K	67%
Beta	0.18
Analysts	Sell
Price Target	$14.00